Announcements Trials
Browse Landscape

Phase

Phase 2 67Phase 1 39Phase 1/2 30Phase 3 26Phase 2/3 5Phase 4 2Phase NA 1Phase EARLY_PHASE1 1

Status

Unknown 1Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 5NIH 3

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 4Dermatologic 1

Conditions

Glioblastoma 4Recurrence 1Melanoma 1Astrocytoma 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9Trastuzumab 8anlotinib 7Injections 7Rituximab 6venetoclax 5atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Azacitidine 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Temozolomide × Clear all
NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT06105619 2026-01-20

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Beijing Pearl Biotechnology Limited Liability Company

Phase 2/3 Active not recruiting
84 enrolled
CNS

Glioblastoma

NCT07349693 2026-01-20

Cerebraca-02/3

Everfront Biotech Co., Ltd.

Phase 2/3 Not yet recruiting
175 enrolled
CNS

Glioblastoma

NCT03008148 2021-05-11

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Johnpro Biotech, Inc.

Phase 2/3 Unknown
288 enrolled
CNS

Glioblastoma

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated
403 enrolled
CNS

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡